BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F. Biliary tract cancer: current challenges and future prospects. Cancer Manag Res. 2019;11:379-388. [PMID: 30643463 DOI: 10.2147/cmar.s157156] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lei C, Peng X, Gong X, Fan Y, Wu S, Liu N, Li L, Huang J, Zheng G, Long Z. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis. Aging (Albany NY) 2019;11:12568-80. [PMID: 31881008 DOI: 10.18632/aging.102588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 38.0] [Reference Citation Analysis]
3 Dee EC, Freret ME, Horick N, Raldow AC, Goyal L, Zhu AX, Parikh AR, Ryan DP, Clark JW, Allen JN, Ferrone CR, Fernandez-Del Castillo C, Tanabe KK, Drapek LC, Hong TS, Qadan M, Wo JY. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol 2020;27:5161-72. [PMID: 32740733 DOI: 10.1245/s10434-020-08967-9] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Abe K, Uwagawa T, Hamura R, Shirai Y, Yasuda J, Furukawa K, Shiozaki H, Onda S, Gocho T, Ikegami T. Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer during chemotherapy: a case-control study. Med Oncol 2022;39:66. [PMID: 35478069 DOI: 10.1007/s12032-021-01625-4] [Reference Citation Analysis]
5 Kim SY, Lee HS, Bang SM, Han DH, Hwang HK, Choi GH, Chung MJ, Kim SU. Serum Dickkopf-1 in Combined with CA 19-9 as a Biomarker of Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:1828. [PMID: 33921232 DOI: 10.3390/cancers13081828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
7 Sun H, Qi X. The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. Discov Onc 2022;13. [DOI: 10.1007/s12672-022-00536-8] [Reference Citation Analysis]
8 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
9 Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Uson PLS, Nagalo BM, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol 2020;85:1063-78. [PMID: 32440762 DOI: 10.1007/s00280-020-04079-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89. [PMID: 32953160 DOI: 10.21037/jgo-20-203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Wu CE, Huang WK, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy. Cancers (Basel) 2021;13:3139. [PMID: 34201707 DOI: 10.3390/cancers13133139] [Reference Citation Analysis]
12 Ettrich TJ, Schwerdel D, Dolnik A, Beuter F, Blätte TJ, Schmidt SA, Stanescu-Siegmund N, Steinacker J, Marienfeld R, Kleger A, Bullinger L, Seufferlein T, Berger AW. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep 2019;9:13261. [PMID: 31519967 DOI: 10.1038/s41598-019-49860-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
13 Dilek ON, Güngör F, Acar T, Atay A, Karasu Ş, Bağ H, Dilek FH. The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature. Indian J Surg 2020;:1-7. [PMID: 32410790 DOI: 10.1007/s12262-020-02259-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cao L, Prithviraj P, Shrestha R, Sharma R, Anaka M, Bridle KR, Kannourakis G, Crawford DHG, Jayachandran A. Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study. J Clin Med 2021;10:2191. [PMID: 34069452 DOI: 10.3390/jcm10102191] [Reference Citation Analysis]
15 Möhring C, Feder J, Mohr RU, Sadeghlar F, Bartels A, Mahn R, Zhou T, Marinova M, Feldmann G, Brossart P, von Websky M, Matthaei H, Manekeller S, Glowka T, Kalff JC, Weismüller TJ, Strassburg CP, Gonzalez-Carmona MA. First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis. Front Oncol 2021;11:717397. [PMID: 34858809 DOI: 10.3389/fonc.2021.717397] [Reference Citation Analysis]
16 Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv 2020;6:eaaz3221. [PMID: 32494639 DOI: 10.1126/sciadv.aaz3221] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
17 Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. [PMID: 32576609 DOI: 10.1136/esmoopen-2020-000682] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
18 Nie C, Lv H, Xing Y, Chen B, Xu W, Wang J, Chen X. The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study. BMC Cancer 2021;21:189. [PMID: 33622272 DOI: 10.1186/s12885-021-07907-4] [Reference Citation Analysis]
19 Khankhel ZS, Goring S, Bobiak S, Lamy FX, Nayak D, Garside J, Reese ES, Schoenherr N. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncol 2022. [PMID: 35387496 DOI: 10.2217/fon-2021-1302] [Reference Citation Analysis]
20 Wu Q, Fan H, Lang R, Li X, Zhang X, Lv S, He Q. Overexpression of 14-3-3σ Modulates Cholangiocarcinoma Cell Survival by PI3K/Akt Signaling. Biomed Res Int 2020;2020:3740418. [PMID: 32685476 DOI: 10.1155/2020/3740418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T. Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:2804. [PMID: 34199886 DOI: 10.3390/cancers13112804] [Reference Citation Analysis]
22 Feng F, Cheng Q, Li B, Liu C, Wang H, Li B, Xu X, Yu Y, Chen Z, Wu X, Dong H, Chu K, Xie Z, Gao Q, Xiong L, Li F, Yi B, Zhang D, Jiang X. Establishment and characterization of 38 novel patient-derived primary cancer cell lines using multi-region sampling revealing intra-tumor heterogeneity of gallbladder carcinoma. Hum Cell 2021;34:918-31. [PMID: 33813726 DOI: 10.1007/s13577-021-00492-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]